---
title: AlphaGenome 2 Bridges Single-Cell Biology and Human Genetics
seo_title: 'AlphaGenome 2 Released: AI Model Predicts DNA Variants in Ce'
meta_description: Discover AlphaGenome 2, the next-gen AI DNA sequence model predicting
  genetic variant effects across hundreds of human cell types and disease states.
social_hook: AlphaGenome 2 is here. By training on over 100 million single-cell profiles,
  this next-gen AI model predicts how DNA variants impact specific human cell types
  and disease states like never before.
slug: alphagenome-2-bridges-single-cell-biology-and-human-genetics-431152
category: AI & Autonomy
seo_tags:
- AlphaGenome 2
- Genomics AI
- Single-Cell Biology
- Human Genetics
- Gene Expression
- Drug Discovery
image_url: https://lh3.googleusercontent.com/VPOhADdGu1T7kK_gWBiGzyVawQbKCjpL3-B0L0wxpYCyr8cHxviYmo9Hghy4f1laeIo2YKwuz8E07TR9HWWk2b0EONi0uvju-8TDLHX6YWHG4dXe3w=w528-h297-n-nu-rw-lo
source_url: https://deepmind.google/blog/alphagenome-2-deciphering-how-cells-read-dna-to-better-understand-disease/
published_at: Wed, 11 Nov 2026 15:00:15 +0000
reading_time: 7
executive_summary: AlphaGenome 2 represents a major leap in genomic AI by shifting
  from broad tissue averages to high-resolution single-cell predictions. Trained on
  over 107 million individual cell profiles, the conditional architecture allows researchers
  to evaluate how genetic variants impact specific, disease-relevant cell types. The
  platform is now available for non-commercial research via API and in private preview
  for commercial partners.
key_takeaways:
- AlphaGenome 2 processes 1-million-letter DNA sequences conditionally, using specific
  biological states as inputs at every architecture stage.
- The model was trained on more than 107 million individual cell profiles across 68
  tissues, integrating bulk and single-cell data.
- It identifies nearly twice as many variants that alter gene expression in specialized
  cells compared to previous iterations.
- The platform generalizes to entirely new or unseen single-cell experiments without
  requiring retraining, boosting drug discovery pipelines.
article_url: articles/alphagenome-2-bridges-single-cell-biology-and-human-genetics-431152.html
draft: false
posted_to_discord: true
---

<h2>Scaling the Genomic Resolution Frontier</h2>
<p>Every somatic cell in the human body carries an identical DNA blueprint, yet distinct cell types and dynamic states—such as a contracting heart muscle cell or an immune cell combatting pathogens—utilize vastly different gene expression programs to execute their biological functions. While global initiatives like the Human Cell Atlas have mapped these expression profiles across millions of cells, predicting precisely how subtle genetic variants alter this expression remains a foundational hurdle in human genetics and clinical diagnostics. Addressing this computational bottleneck, the release of AlphaGenome 2 introduces a next-generation DNA sequence model designed to bridge single-cell biology and human genetics, providing researchers with unprecedented predictive resolution.</p>

<h2>Architectural Shift from Parallel to Conditional Processing</h2>
<p>The original AlphaGenome framework consumed a one-million-letter DNA sequence and projected properties across thousands of bulk tissue experiments simultaneously in a parallel architecture. While computationally efficient, this broad-brush approach strained model capacity and obscured subtle regulatory divergences between closely related cell types. AlphaGenome 2 fundamentally re-engineers this paradigm by adopting a conditional architecture. Alongside the standard million-letter DNA input, the model integrates a target biological condition—defined by tissue, cell type, or physiological state—into every stage of its neural network. This conditional design enables precise cross-modality imputation, allowing researchers to input a single measured metric, such as single-cell gene activity, and accurately predict unmeasured properties like chromatin accessibility.</p>

<blockquote class="editorial-pullquote">"By moving from broad tissue averages to specialized single-cell resolution, AlphaGenome 2 transforms static cell atlases into a dynamic predictive engine for human genetics and therapeutic discovery."</blockquote>

<h2>Unlocking Specialized Cell States and Disease Variants</h2>
<p>Trained on more than 107 million individual cell profiles spanning 68 distinct tissues, AlphaGenome 2 moves past legacy bulk tissue averages to resolve molecular activity inside specialized cellular environments. The model successfully predicts core experimental readouts of DNA function, including gene expression, histone modifications, chromatin accessibility, and newly added DNA methylation profiles. Because of this specialized capacity, AlphaGenome 2 identifies nearly twice as many genetic variants that alter gene expression within specific cell subsets compared to its predecessor. This granular visibility is critical for uncovering rare disease drivers that would otherwise be lost in aggregate tissue data.</p>

<h2>Generalizing Across Unseen Biological Perturbations</h2>
<p>A defining capability of AlphaGenome 2 is its capacity to adapt to novel single-cell data without requiring expensive model retraining. Scientists can upload a single-cell RNA sequencing snapshot comprising just a few dozen cells, which the system compresses into a cell state representation to condition the model on previously unseen biological states. For example, when tested against unseen single-cell data from a COVID-19 mRNA vaccine study, the platform successfully distinguished vaccine-activated immune T cells from resting populations. Furthermore, it revealed that a specific genetic variant linked to severe COVID-19 disrupts gene activity with heightened intensity when cells occupy that activated state.</p>

<h2>Accelerating Downstream Therapeutic Pipelines</h2>
<p>Connecting the thousands of trait- and disease-associated variants identified through genome-wide association studies (GWAS) to actionable drug discovery programs has traditionally required massive computational investments. By precomputing AlphaGenome 2 predictions for trait-associated variants across hundreds of human cell and tissue conditions, the platform bridges this gap directly for translational researchers. As biomedical consortia continue mapping the human body at single-cell resolution, integration with advanced computational frameworks—including upcoming agentic developer platforms—will further cement these models as indispensable instruments for decoding the genetic basis of human disease.</p>
